$538.60
-4.02-0.74%
At close: Nov 13, 4:00 PM EST
$537.00
-1.60-0.3%
After Hours: 7:55 PM EST
Vertex Pharmaceuticals Inc
VRTXNASDAQ
Vertex Pharmaceuticals (VRTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $4.76 | $4.70 | 1.28 % |
| Q2 | Aug 3, 2026 | $4.73 | $4.63 | 2.16 % |
| Q1 | May 4, 2026 | $4.47 | $4.18 | 6.94 % |
| Q4 | Feb 12, 2026 | $5.03 | $4.85 | 3.71 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $3.44B | $3.43B | 0.38 % |
| Q2 | Aug 3, 2026 | $3.33B | $3.21B | 3.74 % |
| Q1 | May 4, 2026 | $2.99B | $2.99B | -0.24 % |
| Q4 | Feb 12, 2026 | $3.19B | $3.17B | 0.54 % |
Vertex Pharmaceuticals (VRTX) last issued guidance on November 2, 2026 for fiscal year 2026. The company guided revenue in the range of $13.15B - $13.25B for the period.
Compared to prior guidance, Vertex Pharmaceuticals maintained its revenue forecast from a prior range of $13.1B - $13.2B.
Vertex Pharmaceuticals has issued 16 guidance updates between February 7, 2023 and November 2, 2026. During this period, the company raised its outlook 5 times, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $4.70 | $4.63 | $4.18 | $4.85 |
| Actual | $4.76 | $4.73 | $4.47 | $5.03 |
| Surprise | +1.28% | +2.16% | +6.94% | +3.71% |
| Revenue | ||||
| Estimate | $3.43B | $3.21B | $2.99B | $3.17B |
| Actual | $3.44B | $3.33B | $2.99B | $3.19B |
| Surprise | +0.38% | +3.74% | -0.24% | +0.54% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $4.00 | $4.60 | $4.49 | $4.67 |
| Revenue | ||||
| Consensus | $3.49B | $3.46B | — | — |
